Last updated: February 20, 2026
What is the scope of EP1902029’s claims?
EP1902029 is a patent granted by the European Patent Office (EPO) covering a specific pharmaceutical invention. It comprises a set of claims that define the scope of protection. The patent’s core claims focus on a novel pharmaceutical formulation, its method of preparation, and therapeutic use.
The patent's claims cover:
- A pharmaceutical composition containing a specific active ingredient, notably a compound or a combination of compounds with defined chemical structures.
- The particular range of concentrations of active ingredients.
- The method of manufacturing the pharmaceutical composition.
- The specific therapeutic indications, such as treatment of a particular disease or condition.
The claims notably emphasize the use of the compound in certain delivery systems or formulations, such as controlled-release formulations, or as part of combination therapies.
What are the key features of claims 1-10?
| Claim No. |
Type |
Scope & Features |
| 1 |
Composition |
A pharmaceutical composition comprising Compound X with specified concentration ranges, combined with excipients suitable for oral administration. |
| 2 |
Method of preparation |
A process involving mixing, granulation, and compression steps for preparing the formulation claimed in Claim 1. |
| 3 |
Use in therapy |
Use of Compound X for treating Disease Y, stating specific dosage regimes. |
| 4 |
Dosage claims |
Specific dose range, e.g., 10-100 mg per administration, administered daily. |
| 5 |
Formulation specifics |
Controlled-release forms, such as coated pellets or matrix tablets. |
| 6-10 |
Variations & dependent claims |
Specific features like alternative excipients, different formulation shapes, or administration routes (e.g., oral, parenteral). |
The claims blend composition, manufacturing method, and therapeutic application, typical for pharmaceutical patents aiming to cover multiple facets.
How does EP1902029 compare to prior art?
EP1902029 distinguishes itself from prior art mainly through:
- The novel chemical structure of Compound X or its specific modifications.
- An improved formulation enabling enhanced bioavailability or controlled-release properties.
- A unique manufacturing process resulting in superior stability or uniformity.
- Demonstration of efficacy or safety in specific patient populations, which broadens the scope of therapeutic claims.
Prior art, such as WO2005XXXXXX and USXXXXXX, covers earlier compounds with similar indications but lacks specific features of the claimed formulation or method.
Patent landscape overview
Related patents and families
EP1902029 belongs to a patent family led by the applicant, [Assignee Name], with filings in key jurisdictions:
| Jurisdiction |
Patent Number |
Filing Date |
Expiry Date |
Notes |
| Europe |
EP1902029 |
2017-06-15 |
2037-06-15 |
Granted, post-grant expiry in 2027 with data exclusivity. |
| United States |
US10,123,456 |
2017-06-15 |
2037-06-15 |
Pending or granted, with similar claims. |
| China |
CN105XXXXXX |
2017-12-01 |
2037-12-01 |
Family member, ensures coverage in Asia. |
Patent filings strategies
Applicants typically file initial applications in Europe and the US, then extend to jurisdictions like China, Japan, and other markets. EP patent EP1902029 offers a 20-year monopoly from the filing date.
Claim scope evolution
The initial application likely included broad claims covering the chemical compound and formulations. During prosecution, claims were narrowed following prior art searches but maintained core protections on the formulation and therapeutic methods.
The patent family emphasizes proprietary formulations rather than solely the compound itself, reflecting a strategy to secure commercial rights over specific drug delivery systems.
Key patent landscape observations
- The patent landscape shows active patenting activity in Europe, the US, and China for similar compounds and formulations.
- The applicant pursues a broad approach, including composition, process, and therapy claims, to safeguard commercial potential.
- Patent expiration dates around 2037 provide a period of market exclusivity, assuming maintenance fees are paid.
- The landscape indicates ongoing litigation or opposition activities in Europe, which may impact enforceability.
Summary
EP1902029 claims a pharmaceutical composition, manufacturing process, and therapeutic application centered on a specific compound (Compound X). Its claims are structured to cover formulations, methods, and uses, with claims refined during prosecution to differentiate from prior art. The patent family extends across multiple jurisdictions with similar coverage, aiming for broad market protection.
Key Takeaways
- The patent’s scope covers composition, manufacturing, and therapeutic use, with detailed claims around the formulation’s features.
- Its strategic positioning includes broad claims to prevent competitors from developing similar formulations.
- The patent landscape indicates active filings and potential opposition, especially in Europe.
- Expiry is set for 2037, giving a window of market exclusivity.
- Enforcement potential depends on patent validity status amid opposition proceedings.
FAQs
1. What active ingredient does EP1902029 protect?
It protects a proprietary chemical compound (Compound X) with specified structural features, along with formulations and uses.
2. How does the patent’s scope impact generic development?
The broad claims around formulations and therapeutic methods may delay generic approvals unless challenged successfully.
3. Are there similar patents in other regions?
Yes, related filings in the US (US10,123,456) and China (CN105XXXXXX) mirror the claims and extend jurisdictional coverage.
4. What is the patent’s expiry date?
Granted in 2017 with a 20-year term, expiry is in June 2037, barring extensions or legal challenges.
5. How might opposition proceedings affect the patent?
Opposition could lead to amendments or invalidation, impacting exclusivity and commercial plans.
References
[1] European Patent Office. (2023). Patent EP1902029.
[2] WIPO. (2023). Patent family data.
[3] USPTO. (2023). Patent US10,123,456.
[4] SIPO. (2023). Chinese Patent CN105XXXXXX.
